Investment Rating - The report maintains a rating of "Buy" for the small nucleic acid drug industry, indicating an expected investment return exceeding 15% over the next 6-12 months [5]. Core Insights - The small nucleic acid drug market, primarily driven by SiRNA and ASO, is experiencing rapid growth from technological breakthroughs to large-scale commercialization, with a compound annual growth rate (CAGR) of 217.8% from 2016 to 2021, increasing from $0.1 billion to $3.25 billion [1]. - The global market for oligonucleotide drugs is projected to exceed $15 billion by 2026, with a CAGR of 35% from 2020 to 2025 [1]. - BlueX Technology is a key player in solid-phase synthesis carriers, developing a comprehensive "synthesis-purification" platform for small nucleic acids and peptides, with significant investments planned for expanding its capabilities [2]. - Lianhua Technology is leveraging its established small molecule CDMO system to expand into the small nucleic acid business, with the global CDMO market expected to surpass $120 billion by 2024, growing at a CAGR of approximately 9.5% [3]. Summary by Sections Small Nucleic Acid Drug Market - The small nucleic acid drug market is characterized by a variety of drug types, including SiRNA and ASO, with a significant increase in market size and growth rate [1]. - The market is expected to continue its upward trajectory, driven by advancements in technology and increased demand for oligonucleotide drugs [1]. BlueX Technology - BlueX Technology has established itself as a leader in solid-phase synthesis carriers, creating a full-chain supply capability for small nucleic acids and peptides [2]. - The company plans to invest 1.15 billion yuan in a new GMP-standard biopharmaceutical park and expand its international presence [2]. Lianhua Technology - Lianhua Technology is expanding its CDMO services to include small nucleic acids, capitalizing on the growing demand for biopharmaceuticals and small molecule intermediates [3]. - The company has made significant progress in international market expansion and is focusing on developing new business areas, including peptide CDMO and radioactive drugs [3].

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the small nucleic acid drug industry, specifically the production and cost structure of active pharmaceutical ingredients (APIs) and formulations [1][2][3]. Cost Structure and Value Distribution - The cost structure of small nucleic acid drugs shows that the API accounts for 13%-14% of the terminal sales cost, while the formulation part constitutes 20% [1][2]. - The primary costs arise from the commercial GMP (Good Manufacturing Practice) system rather than just raw materials [2]. - The production of small nucleic acid drugs involves key intermediates and raw materials, including carriers (e.g., L96, CCTP), monomers (e.g., phosphoramidite), and solvent reagents [1][4]. Key Components and Their Cost Impact - Monomer costs represent 30%-40% of total production costs, while solvent reagents account for approximately 30% [1][5]. - The delivery system, such as GalNAc, contributes about 6% to the total production cost [6]. - The market price for L96 ranges from 400,000 to 500,000 yuan per kilogram, with leading manufacturers like Zhaowei charging up to 700,000 yuan per kilogram [7]. Production Requirements and Challenges - Producing 1 gram of siRNA API requires 30-40 grams of monomer and about 100 liters of acetonitrile, while producing 1 gram of ASO requires about 20 grams of monomer [8][10]. - Different modifications affect the synthesis yield, necessitating a re-evaluation of processes [11]. - Key raw materials such as core monomers, carriers, coupling reagents, and critical solvents cannot be easily changed without thorough justification and regulatory approval [12]. Production Technology and Market Dynamics - The mainstream production technology for small nucleic acid APIs is solid-phase synthesis, which is well-established [13]. - Domestic CDMO (Contract Development and Manufacturing Organization) companies include Hequn Pharmaceutical and Kailaiying, while global leaders include Alice Belgium, Agent Biotech, and Sermon XT [15][16]. - The tension in China-U.S. relations presents structural opportunities for China's CDMO industry, which could become the second-largest supplier globally due to its cost advantages and scale of production [18]. Clinical Stage Cost Variations - There are significant cost differences between early-stage and late-stage clinical trials, with late-stage trials incurring higher costs due to stricter impurity control and product consistency requirements [14]. Conclusion - The small nucleic acid drug industry is characterized by a complex cost structure influenced by various factors, including the type of product, production technology, and regulatory requirements. The industry is poised for growth, particularly in the context of evolving global supply chains and increasing demand for high-quality CDMO services.

Summary of Key Points from the Conference Call Industry Overview - The small nucleic acid drug market has significant growth potential, expected to reach a scale of hundreds of billions of dollars in the long term, particularly in chronic and metabolic disease areas, presenting over ten billion dollars in investment opportunities for the upstream and downstream industry chain [1][2][6]. Market Growth and Projections - The global small nucleic acid drug market size grew from $2.7 billion in 2019 to $5.1 billion in 2024, with an anticipated compound annual growth rate (CAGR) of nearly 26%, projected to reach $40 billion by 2035 [1][6]. Key Players and Competitive Landscape - Major multinational corporations (MNCs) such as Novartis and Sanofi dominate the commercialization of small nucleic acid drugs, leveraging their patent portfolios, sales channels, and product layouts to maintain stable gross margins [1][3][10]. - The entry barrier for domestic Chinese companies into the supply chains of these MNCs is high, with traditional raw material suppliers facing challenges due to the high production costs associated with small nucleic acid drugs [3][8]. Advantages of Small Nucleic Acid Drugs - Small nucleic acid drugs offer several significant advantages: 1. Precise targeting of genetic origins, directly regulating gene expression to prevent the production of pathogenic proteins [5]. 2. Broad target range, including traditionally undruggable targets such as non-coding RNA and mutated genes [5]. 3. Long-lasting treatment effects, suitable for chronic disease management [5]. 4. Shorter research and development cycles, allowing for rapid design and reduced costs [5]. 5. Compatibility with combination therapies and personalized medicine [5]. Challenges in Production - The production of small nucleic acid drugs faces several challenges: 1. Limited production throughput due to the solid-phase synthesis method [9]. 2. High costs of raw materials, which can account for a significant portion of overall production costs [9]. 3. Dependency on China for key raw materials, complicating supply chain management [9]. 4. High industrialization requirements as more drugs enter late-stage clinical trials or commercialization [9]. Investment Opportunities - The manufacturing segment of small nucleic acid drugs represents a considerable investment opportunity, as production costs account for about 20% of terminal sales [8]. - China is expected to remain a major supplier of small molecule raw materials and intermediates due to its advantages in solid-phase synthesis and monomer production [8]. Key Year: 2025 - The year 2025 is highlighted as a critical period for small nucleic acid drug development, with multiple key drugs entering Phase III clinical trials and expected to receive approvals across various indications, including cardiovascular diseases, non-alcoholic fatty liver disease, weight loss, and tumors [7][10]. Notable Developments and Strategies - Novartis has been actively investing and acquiring in the small nucleic acid space, with plans to advance seven small nucleic acid drugs through clinical trials from 2023 to 2025, encompassing 19 pipelines [10][14]. - Other large multinational companies, including Pfizer, Roche, Eli Lilly, Merck, and Novo Nordisk, are also making significant moves in this burgeoning market [10][13]. Conclusion - The small nucleic acid drug industry is poised for substantial growth, driven by innovative therapeutic advantages and increasing market demand, while facing challenges that require strategic management and investment in production capabilities.